SAB Biotherapeutics (SABS) Competitors

$3.92 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.91 -0.01 (-0.26%)

As of 07/2/2026 06:00 PM Eastern

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

SAB Biotherapeutics presently has a consensus price target of $12.00, indicating a potential upside of 206.12%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 96.12%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SAB Biotherapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

SAB Biotherapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A
Lexicon Pharmaceuticals	$49.80M	20.69	-$50.34M	-$0.07	N/A

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Lexicon Pharmaceuticals and 0 mentions for SAB Biotherapeutics. Lexicon Pharmaceuticals' average media sentiment score of 1.82 beat SAB Biotherapeutics' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Neutral
Lexicon Pharmaceuticals	Very Positive

SAB Biotherapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. SAB Biotherapeutics' return on equity of -0.29% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Summary

SAB Biotherapeutics beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to OPKO Health?

SAB Biotherapeutics (NASDAQ:SABS) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

SAB Biotherapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

SAB Biotherapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. SAB Biotherapeutics' return on equity of -0.29% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
OPKO Health	-36.63%	-16.78%	-10.98%

SAB Biotherapeutics has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A
OPKO Health	$581.12M	1.98	-$225.68M	-$0.27	N/A

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SAB Biotherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 206.12%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 1.97%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, OPKO Health's average media sentiment score of 0.20 beat SAB Biotherapeutics' score of 0.00 indicating that OPKO Health is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Neutral
OPKO Health	Neutral

Summary

SAB Biotherapeutics beats OPKO Health on 9 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Geron?

Geron (NASDAQ:GERN) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Geron presently has a consensus target price of $2.50, suggesting a potential upside of 83.82%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 206.12%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Geron had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 2 mentions for Geron and 0 mentions for SAB Biotherapeutics. Geron's average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Geron	Neutral
SAB Biotherapeutics	Neutral

73.7% of Geron shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SAB Biotherapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.74	-$83.50M	-$0.11	N/A
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A

Geron has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

SAB Biotherapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. SAB Biotherapeutics' return on equity of -0.29% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

SAB Biotherapeutics beats Geron on 10 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

SAB Biotherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 206.12%. Rigel Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 40.75%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe SAB Biotherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Rigel Pharmaceuticals had 5 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 0 mentions for SAB Biotherapeutics. Rigel Pharmaceuticals' average media sentiment score of 0.36 beat SAB Biotherapeutics' score of 0.00 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Neutral
Rigel Pharmaceuticals	Neutral

Rigel Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07

SAB Biotherapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 121.50% compared to SAB Biotherapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats SAB Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

SAB Biotherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 206.12%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 43.96%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71

SAB Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	227.06	$13.27M	-$2.11	N/A
Ironwood Pharmaceuticals	$296.15M	2.38	$24.02M	$0.60	7.22

Ironwood Pharmaceuticals has a net margin of 28.26% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -0.29% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

7.8% of SAB Biotherapeutics shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for Ironwood Pharmaceuticals and 0 mentions for SAB Biotherapeutics. Ironwood Pharmaceuticals' average media sentiment score of 1.21 beat SAB Biotherapeutics' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Neutral
Ironwood Pharmaceuticals	Positive

Summary

Ironwood Pharmaceuticals beats SAB Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$299.74M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.86	21.61	28.02	24.70
Price / Sales	227.06	340.19	540.37	99.49
Price / Cash	11.47	147.12	49.26	57.09
Price / Book	1.23	8.66	10.96	6.46
Net Income	$13.27M	$23.81M	$3.57B	$337.01M
7 Day Performance	3.16%	3.39%	2.12%	1.69%
1 Month Performance	15.98%	10.81%	5.25%	3.81%
1 Year Performance	126.59%	62.61%	33.29%	23.90%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	2.7073 of 5 stars	$3.92 flat	$12.00 +206.1%	+126.6%	$299.74M	$1.32M	N/A	140
LXRX Lexicon Pharmaceuticals	2.1289 of 5 stars	$2.40 -9.1%	$4.55 +89.6%	+154.9%	$1.17B	$49.80M	N/A	140	News Coverage
OPK OPKO Health	0.9773 of 5 stars	$1.50 -0.7%	$1.55 +3.3%	+13.0%	$1.14B	$606.90M	N/A	1,373
GERN Geron	1.4756 of 5 stars	$1.28 -1.5%	$2.50 +95.3%	-4.6%	$833.98M	$183.88M	N/A	70
RIGL Rigel Pharmaceuticals	3.8736 of 5 stars	$39.12 +0.2%	$54.50 +39.3%	+104.7%	$722.32M	$294.28M	2.09	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to OPKO Health?

Summary

How does SAB Biotherapeutics compare to Geron?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Do analysts rate SABS or LXRX?

Which has more risk and volatility, SABS or LXRX?

Which has preferable earnings and valuation, SABS or LXRX?

Do insiders and institutionals believe in SABS or LXRX?

Does the media favor SABS or LXRX?

Is SABS or LXRX more profitable?

Summary

How does SAB Biotherapeutics compare to OPKO Health?

Which has more risk and volatility, SABS or OPK?

Is SABS or OPK more profitable?

Which has better earnings and valuation, SABS or OPK?

Do institutionals & insiders hold more shares of SABS or OPK?

Do analysts recommend SABS or OPK?

Does the media refer more to SABS or OPK?

Summary

How does SAB Biotherapeutics compare to Geron?

Do analysts recommend GERN or SABS?

Does the media favor GERN or SABS?

Do insiders & institutionals hold more shares of GERN or SABS?

Which has stronger earnings & valuation, GERN or SABS?

Which has more volatility and risk, GERN or SABS?

Is GERN or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Do analysts rate SABS or RIGL?

Does the media prefer SABS or RIGL?

Which has better earnings and valuation, SABS or RIGL?

Which has more volatility & risk, SABS or RIGL?

Is SABS or RIGL more profitable?

Do insiders & institutionals have more ownership in SABS or RIGL?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Do analysts recommend SABS or IRWD?

Which has more risk and volatility, SABS or IRWD?

Which has higher earnings & valuation, SABS or IRWD?

Is SABS or IRWD more profitable?

Do insiders and institutionals hold more shares of SABS or IRWD?

Does the media refer more to SABS or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools